# InsytAI — Full Content Index > Canonical site: https://new.insytai.com/ > Summary index: https://new.insytai.com/llms.txt --- ## Singapore's AI-SaMD Exemption Pathway: What Public Healthcare Institutions Need to Know in 2026 - URL: https://new.insytai.com/blog/singapore-ai-samd-exemption-pathway-hsa-public-healthcare-2026 - Date: 2026-06-13 If you're leading AI development in a Singapore public healthcare institution, you now have a regulatory pathway that didn't exist two years ago. The Health Sciences Authority (HSA) has finalized an exemption from manufacturer licensing and product registration requirements for selected AI-enabled Software as a Medical Device (AI-SaMD) developed by public healthcare entities [4]. This isn't a blanket sandbox—it's a tightly scoped pathway with specific eligibility criteria, and understanding the boundaries is critical before you commit engineering resources. This post is for clinical AI teams, hospital CIOs, medical device regulatory leads, and healthtech founders in Singapore navigating the SaMD regulatory landscape. ## Key takeaways - HSA's AI-SaMD exemption pathway applies only to public healthcare institutions developing AI-SaMD for internal use within their own facilities [4] - The exemption does not waive clinical validation, risk management, or post-market surveillance obligations—it streamlines administrative licensing, not safety requirements [4] - Singapore's broader AI governance framework (PDPC/IMDA Model AI Governance Framework) remains relevant for transparency, explainability, and human oversight even under the exemption [1] - Commercial deployment or use outside the developing institution still requires full HSA registration—this is not a path to market [4] - The pathway aligns with global adaptive AI/ML regulatory thinking (FDA's approach to continuously learning algorithms) but remains more conservative in scope [2] ## What the HSA AI-SaMD exemption actually covers The exemption responds to a practical problem: public healthcare institutions developing AI tools for internal clinical use faced the same regulatory burden as commercial medical device manufacturers, even when the software never left the hospital network [4]. Under the finalized pathway, eligible AI-SaMD developed by public healthcare entities can be exempted from: - Manufacturer licensing requirements - Product registration requirements But—and this is critical—exemption does not mean deregulation. The HSA response to public consultation makes clear that institutions must still demonstrate: - Appropriate risk management processes - Clinical validation and performance monitoring - Adverse event reporting - Cybersecurity and data protection measures [4] We've seen teams misinterpret "exemption" as "no oversight." That's a compliance failure waiting to happen. The exemption streamlines bureaucratic licensing; it does not reduce your obligation to prove safety and effectiveness. ## Who qualifies—and who doesn't Eligibility is narrow: **Eligible:** - Public healthcare institutions (restructured hospitals, national specialty centers, polyclinics under National Healthcare Group, SingHealth, National University Health System) - AI-SaMD developed in-house or in collaboration with academic/research partners - Software used exclusively within the developing institution's clinical environment - Tools that do not involve commercial distribution or cross-institutional deployment at launch [4] **Not eligible:** - Private hospitals or clinics - Commercial healthtech vendors (even if partnering with a public institution) - AI-SaMD intended for multi-site deployment from day one - Software that will be licensed or sold to other healthcare providers If your roadmap includes eventual commercialization, plan for full HSA registration from the start. Retrofitting compliance is more expensive than building it in. ## How this fits with Singapore's AI governance framework The exemption pathway operates within Singapore's broader AI governance ecosystem. The Personal Data Protection Commission (PDPC) and Infocomm Media Development Authority (IMDA) Model AI Governance Framework [1] establishes principles for transparency, explainability, and human oversight that remain relevant even when HSA licensing is exempted. In practice, this means: - **Explainability requirements:** Clinical users need to understand AI recommendations. The Model AI Governance Framework emphasizes interpretability and auditability [1], which aligns with clinical safety obligations under the exemption. - **Human-in-the-loop:** The framework's guidance on human oversight maps directly to clinical decision-making workflows. AI-SaMD under the exemption still requires clinician review and final decision authority [1]. - **Bias and fairness:** The PDPC framework's focus on fairness testing is not optional—it's part of demonstrating that your AI-SaMD is safe across patient populations [1]. We treat the Model AI Governance Framework as a practical checklist, not a compliance checkbox. When HSA asks for risk management documentation, governance artifacts (model cards, bias audits, drift monitoring logs) become evidence of due diligence. ## What the FDA's adaptive AI/ML approach tells us about the future Singapore's pathway is more conservative than the FDA's proposed framework for continuously learning AI/ML-enabled SaMD, but the regulatory direction is similar [2]. The FDA envisions a "predetermined change control plan" that allows algorithm updates without new premarket submissions, provided the changes stay within a defined performance envelope [2]. HSA has not yet adopted this adaptive model for the exemption pathway. Currently, significant algorithm changes—retraining on new data, architecture modifications, expanded indications—likely trigger a new review, even under exemption [4]. For teams building AI-SaMD in Singapore public healthcare institutions, this means: - **Version control discipline:** Document every model version, training dataset, and performance metric. If HSA requests retrospective evidence of a change, you need an audit trail. - **Change impact assessment:** Establish internal thresholds for what constitutes a "significant" change. We use performance delta (>5% AUC shift), population shift (new demographic or clinical subgroup), and indication expansion as triggers for re-review. - **Monitor global regulatory convergence:** As FDA, UK MHRA, and EU MDR frameworks evolve toward adaptive AI/ML pathways, HSA may follow. Build systems that can adapt to more flexible change control in future. ## Why this matters in Singapore and Asia Singapore's public healthcare system is a testbed for clinical AI at scale. National Electronic Health Record (NEHR) integration, centralized data governance, and a tech-forward clinical culture create conditions for rapid AI deployment—but regulatory friction has historically slowed internal innovation. The exemption pathway reduces time-to-deployment for hospital-developed AI tools, which matters for: - **Operational AI:** Bed management, patient flow, resource allocation tools that don't require external commercialization but need clinical integration. - **Clinical decision support:** Risk stratification, early warning systems, diagnostic aids developed by clinician-data scientist teams within institutions. - **Research-to-practice translation:** Academic medical centers can move from research prototypes to clinical pilots without full commercial device registration. For the broader Asia-Pacific region, Singapore's approach may influence regulatory thinking in markets watching HSA as a reference (Malaysia, Thailand, Philippines). If the exemption pathway proves effective, we may see similar frameworks emerge regionally. ## What to do next - **Map your AI-SaMD portfolio to eligibility criteria:** Identify which tools qualify for exemption vs. require full registration. Don't assume—confirm with HSA guidance documents [3] or pre-submission consultation. - **Build governance infrastructure now:** Even if you qualify for exemption, you need risk management, clinical validation, and post-market surveillance processes. Use the Model AI Governance Framework [1] as a starting template. - **Establish change control protocols:** Define what constitutes a significant algorithm change and document your rationale. This becomes your internal policy and external evidence if HSA asks. - **Plan for commercialization from day one:** If there's any chance your AI-SaMD will be used outside your institution, design for full HSA registration requirements. The exemption is not a stepping stone to market. - **Engage HSA early:** Use pre-submission meetings to clarify scope, risk classification, and evidence requirements. Regulatory dialogue is cheaper than post-development rework. ## FAQ ### Can a private hospital use AI-SaMD developed under the exemption by a public institution? No. The exemption applies only to use within the developing public healthcare institution [4]. Cross-institutional deployment, even to another public hospital, requires full HSA registration. ### Does the exemption apply to AI-SaMD developed by a commercial vendor for a public hospital? No. The exemption is for AI-SaMD developed by the public healthcare institution itself, potentially in collaboration with academic or research partners, but not commercial vendors [4]. If a vendor is the legal manufacturer, full registration applies. ### What happens if we want to commercialize an AI-SaMD initially developed under the exemption? You must apply for full manufacturer licensing and product registration before any commercial distribution or use outside your institution [4]. Treat commercialization as a new regulatory pathway, not an extension of the exemption. ### How does this exemption interact with PDPA and data protection requirements? The exemption does not waive Personal Data Protection Act (PDPA) obligations. Patient data governance, consent, and security requirements remain in full force [1]. HSA expects cybersecurity and data protection measures as part of the exemption's risk management obligations [4]. ## Sources [1] Personal Data Protection Commission Singapore. (2020). Model AI Governance Framework. https://www.pdpc.gov.sg/help-and-resources/2020/01/model-ai-governance-framework [2] U.S. Food and Drug Administration. Artificial Intelligence and Machine Learning in Software as a Medical Device. https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-software-medical-device [3] Health Sciences Authority Singapore. Guidance Documents for Medical Devices and Software Medical Devices. https://www.hsa.gov.sg/medical-devices/guidance-documents [4] Health Sciences Authority Singapore. Response to Feedback from Public Consultation on the Proposed Exemption from Manufacturer's Licensing and Product Registration Requirements for Artificial Intelligence. https://www.hsa.gov.sg/announcements/response-to-feedback-from-public-consultation-on-the-proposed-exemption-from-manufacturer-s-licensing-and-product-registration-requirements-for-artificial-intelligence/ --- ## The Patient Voice in Healthcare AI: Why Asia's Hospitals Need Structured Feedback Mechanisms - URL: https://new.insytai.com/blog/the-patient-voice-in-healthcare-ai-why-asias-hospitals-need-structured-feedback- - Date: 2026-06-12 # The Patient Voice in Healthcare AI: Why Asia's Hospitals Need Structured Feedback Mechanisms As healthcare AI tools proliferate across Asian hospitals—from diagnostic imaging algorithms to ambient clinical documentation—a critical stakeholder remains largely absent from deployment decisions: patients themselves. Recent developments at Stanford Health Care in the United States offer a compelling blueprint for how Asian healthcare institutions should rethink their AI governance frameworks, particularly as regulatory environments mature and patient expectations evolve. ## Stanford's Patient Panel Experiment: Key Insights for Asia Stanford Health Care has pioneered a structured approach to soliciting patient feedback on AI tools before implementation [2]. Rather than treating patients as passive recipients of algorithmic care, the institution established patient panels to evaluate proposed AI applications. The results have been revealing: patients and hospitals frequently disagree about AI priorities and acceptable use cases [1]. This divergence matters enormously for Asian healthcare systems. In Singapore, where the Ministry of Health has established AI governance frameworks, and across Southeast Asia where medical imaging AI is being rapidly deployed, the absence of systematic patient input creates three distinct risks: **First, deployment friction.** AI tools approved through purely clinical and administrative channels may face patient resistance at the point of care, undermining adoption rates and return on investment. Stanford's experience demonstrates that patients identify "fault lines" in AI adoption that technical teams miss [2]—concerns about data privacy, algorithm transparency, and the changing nature of the physician-patient relationship. **Second, ethical blind spots.** Clinical teams naturally prioritize accuracy, efficiency, and workflow integration. Patients care deeply about these factors but weight them differently, often elevating concerns about informed consent, data sovereignty, and the preservation of human judgment in critical decisions. Without structured feedback mechanisms, hospitals risk deploying tools that are technically sound but ethically misaligned with patient values. **Third, missed opportunities for co-design.** Patient panels don't simply approve or reject proposals—they reshape them. When patients articulate concerns about specific AI applications, they often suggest modifications or alternative approaches that improve both clinical utility and patient experience. ## Why Asian Healthcare Systems Face Unique Patient Engagement Challenges Asian healthcare contexts present distinct considerations that make patient engagement even more critical—and more complex—than in Western settings. **Cultural factors around medical authority** vary significantly across the region. In many Asian healthcare systems, traditional hierarchies place physicians in positions of unquestioned authority, making it culturally unfamiliar for patients to critique or question clinical tools. Establishing patient panels requires deliberate efforts to create psychologically safe spaces where feedback is genuinely welcomed. **Language and health literacy diversity** across Southeast Asia means that explaining AI systems—already challenging in monolingual contexts—becomes exponentially more difficult. Singapore's multilingual environment, Malaysia's diverse population, and Indonesia's archipelagic complexity all demand patient engagement strategies that go beyond translated consent forms. **Data governance expectations** differ markedly across Asian jurisdictions. Singapore's relatively mature data protection framework contrasts with emerging regulatory environments elsewhere in the region. Patient panels can help hospitals navigate these variations by surfacing community-specific concerns about data sharing, cross-border transfers, and commercial use of health information. ## Practical Implementation Framework for Asian Hospitals Based on Stanford's model and adapted for Asian contexts, healthcare institutions should consider the following structured approach: **Establish representative panels early.** Before deploying medical imaging AI or other patient-facing algorithms, convene panels that reflect the demographic, linguistic, and socioeconomic diversity of the patient population. In Singapore's context, this means ensuring representation across Chinese, Malay, Indian, and other communities. Panel composition should be refreshed regularly to avoid capture by early adopters. **Focus on specific use cases, not abstract principles.** Rather than asking patients about "AI in healthcare" broadly, present concrete scenarios: "This algorithm will analyze your chest X-ray before the radiologist reviews it. The radiologist makes the final decision. Are you comfortable with this workflow?" Specificity generates actionable feedback. **Create tiered engagement for different AI risk levels.** Not every algorithm requires extensive patient consultation. Develop a classification system—perhaps aligned with regulatory risk categories—that determines the appropriate level of patient engagement. High-risk applications (diagnostic AI that might delay treatment, algorithms affecting vulnerable populations) warrant deeper consultation than low-risk workflow tools. **Document and share feedback systematically.** Stanford's approach reveals patterns in patient concerns that inform institutional AI strategy [1][2]. Asian hospitals should similarly aggregate feedback to identify recurring themes, which often point to gaps in communication, consent processes, or technical design. **Integrate patient feedback into governance committees.** Patient panel insights should flow directly into AI governance committees alongside clinical, technical, and regulatory input. This integration ensures patient perspectives shape deployment decisions, not just communication strategies. ## The Business Case for Patient Engagement For hospital CIOs and healthcare executives evaluating the resource investment required for patient panels, the business case is straightforward: **Reduced deployment risk.** Identifying patient concerns before launch is vastly cheaper than managing resistance, reputational damage, or regulatory scrutiny after deployment. Medical imaging AI that patients refuse to accept represents sunk investment. **Competitive differentiation.** As AI becomes ubiquitous in healthcare, patient trust becomes a competitive advantage. Hospitals that demonstrably incorporate patient voices into AI governance can market this transparency to discerning patients and corporate healthcare buyers. **Regulatory alignment.** As Asian regulators mature their AI oversight—Singapore's Health Sciences Authority has signaled increasing attention to algorithm governance—proactive patient engagement positions institutions ahead of likely regulatory requirements around transparency and consent. ## Moving Forward: Building the Infrastructure The current gap in patient engagement around healthcare AI in Asia is not primarily about resources—it's about institutional imagination. Stanford's model demonstrates that structured patient feedback is both feasible and valuable [2]. The question for Asian healthcare leaders is not whether to build these mechanisms, but how quickly they can be established before the next wave of AI deployment. For medical imaging AI specifically—a domain where Asian hospitals have been aggressive adopters—patient panels offer particular value. Radiology AI often operates invisibly to patients, yet fundamentally changes diagnostic pathways. Making these changes visible and soliciting patient input builds trust and surfaces concerns that purely technical validation cannot address. The Stanford experience reveals that patients and hospitals disagree about AI in predictable, patterned ways [1]. These disagreements aren't obstacles—they're valuable signals about where communication, design, or governance needs strengthening. Asian healthcare institutions that build systematic mechanisms to capture and act on these signals will deploy AI more successfully, more ethically, and more sustainably than those that treat patients as passive recipients of algorithmic care. ## Key takeaways - Patients and hospitals often disagree on AI priorities — structured patient panels surface adoption risks early. - Asian hospitals need culturally adapted feedback mechanisms, not direct copies of Western models. - Tier engagement by AI risk level: low-risk workflow tools need lighter consultation than diagnostic AI. - Document patient feedback systematically and feed it into governance committees alongside clinical input. ## FAQ ### Why do Asian hospitals need patient feedback before deploying healthcare AI? Without structured patient input, tools that pass clinical review can still fail at the point of care due to trust, consent, and cultural expectations — especially across Singapore's multilingual populations. ### What can hospitals learn from Stanford's patient panel approach? Stanford shows that patients identify fault lines in AI adoption that technical teams miss, including privacy concerns, transparency expectations, and discomfort with reduced human judgment in critical decisions. ### How should CIOs prioritize patient engagement for medical imaging AI? Imaging AI often runs invisibly to patients but changes diagnostic pathways. Make the workflow visible, present concrete scenarios to panels, and align engagement depth with regulatory risk tier. ## Sources [1] STAT+: Where patients and hospitals disagree about AI — STAT News Health Tech 2026-05-27 https://www.statnews.com/2026/05/27/health-ai-where-patients-hospitals-disagree-ai-prognosis/ [2] STAT+: How Stanford patients help expose 'fault lines' in health AI adoption — STAT News Health Tech 2026-05-27 https://www.statnews.com/2026/05/27/stanford-patient-panels-feedback-on-ai-shaping-health-care/ --- ## The Invisible Layer: Why Medical Imaging AI Fails Before You See the Output - URL: https://new.insytai.com/blog/medical-imaging-ai-acquisition-drift-monitoring-singapore - Date: 2026-06-12 # The Invisible Layer: Why Medical Imaging AI Fails Before You See the Output If you're deploying medical imaging AI in Singapore or Asia, you're likely monitoring model outputs: sensitivity, specificity, false positives flagged for radiologist review. The 2026 ACR-SIIM Practice Parameter now recommends local acceptance testing and ongoing drift monitoring [3]. Registries like ACR Assess-AI track AI outputs using DICOM metadata for context [3]. But a preprint published this week argues that a critical layer sits beneath all of this—and it's currently invisible to your monitoring stack. This post is for hospital CIOs, clinical AI leads, and radiology informatics teams deploying or evaluating medical imaging AI. We'll walk through what acquisition-layer drift is, why it matters, and what you can do about it before your next AI procurement. ## Key takeaways - **Acquisition parameters govern AI performance before the model sees the image**, but DICOM metadata doesn't capture the full acquisition envelope [3] - **Lung-nodule AI shows "kernel-driven measurement instability" and "noise-driven detection fragility"** invisible to standard output monitoring [3] - **Current governance frameworks (NIST AI RMF, ACR-SIIM) focus on output metrics and metadata**, leaving acquisition drift unmonitored [2][3] - **Singapore hospitals deploying imaging AI need acceptance testing that includes acquisition-layer validation**, not just output performance checks - **This isn't theoretical**: the study demonstrates measurable instability in deployed models that passed initial validation [3] ## What is acquisition-layer drift, and why does DICOM metadata miss it? When we talk about AI drift in medical imaging, we usually mean one of two things: data drift (patient population changes) or model drift (performance degrades over time). Both are monitored by tracking outputs—sensitivity drops, false-positive rates climb, radiologists override the AI more often. But a new preprint on lung-nodule AI from June 11, 2026, introduces a third category: **acquisition state drift** [3]. The authors demonstrate that CT reconstruction kernels, noise levels, and other acquisition parameters create "structured, measurable" variation in AI behavior—but this variation is invisible to DICOM metadata [3]. Here's the problem: your DICOM tags tell you manufacturer, model, slice thickness, kVp, mAs. They don't tell you which reconstruction kernel was used, what iterative reconstruction settings were applied, or how much noise is present in the image. Two scans with identical DICOM metadata can produce different AI outputs because the acquisition envelope differs [3]. The study calls this "kernel-driven measurement instability" (nodule size measurements vary) and "noise-driven detection fragility" (nodules appear or disappear) [3]. If your monitoring stack only watches output metrics and DICOM tags, you won't see this until it shows up as unexplained performance drops—or worse, as missed diagnoses. ## Why current governance frameworks don't catch this The NIST AI Risk Management Framework [2] provides a solid structure for managing AI risks to individuals, organizations, and society. It emphasizes measurement, monitoring, and context. The 2026 ACR-SIIM Practice Parameter builds on this, recommending local acceptance testing and ongoing drift monitoring for imaging AI [3]. But both frameworks assume you can measure what matters using available metadata. The lung-nodule study shows this assumption breaks down at the acquisition layer [3]. DICOM metadata is necessary but insufficient. You need ground-truth acquisition parameters—kernel type, reconstruction algorithm version, noise index—and most PACS systems don't store these in queryable fields. This creates a governance gap. You can monitor outputs ("Did the AI flag this nodule?") and context ("What scanner was used?"), but you can't monitor the acquisition envelope ("Was this scan within the training distribution for kernel and noise?"). The result: silent drift that only surfaces when a radiologist catches a miss, or when you run a retrospective audit. For healthcare AI deployment in Singapore, where radiology AI is increasingly common and regulatory scrutiny is rising, this gap is a liability. You're compliant with current best practices, but you're not monitoring the layer where failure begins. ## What acquisition-layer monitoring looks like in practice We've deployed medical imaging AI in hospital settings. Here's what acquisition-layer monitoring requires, based on the study's findings [3] and our own experience: ### 1. Acceptance testing that includes acquisition variation Don't just test the AI on your local data. Test it on scans acquired with different kernels, noise levels, and reconstruction settings. If your CT fleet includes multiple scanner models or software versions, test each combination. Document which acquisition states produce stable performance and which show instability. The lung-nodule study demonstrates that this variation is measurable and structured [3]. You can quantify it during acceptance testing. If the vendor can't provide performance data across acquisition states, that's a red flag. ### 2. Metadata enrichment at acquisition time Work with your radiology IT team to capture acquisition parameters that aren't in standard DICOM tags. Some scanners expose kernel type, reconstruction algorithm, and noise index in private tags or dose reports. Extract these at acquisition time and store them in a queryable database alongside the DICOM metadata. This is infrastructure work, but it's the only way to monitor acquisition drift. Without it, you're flying blind. ### 3. Ongoing monitoring that tracks acquisition state Once you have enriched metadata, monitor AI performance stratified by acquisition state. If sensitivity drops for scans acquired with a specific kernel, you've caught acquisition drift before it becomes a patient safety issue. This requires a monitoring stack that goes beyond vendor-provided dashboards. You need access to raw AI outputs, ground-truth labels (from radiologist reads), and acquisition metadata. Most hospitals don't have this yet. Building it is part of responsible clinical AI deployment. ### 4. Vendor transparency and model cards Ask vendors for model cards that document the acquisition envelope: which kernels, noise levels, and reconstruction algorithms were included in training and validation. If the vendor can't answer, the model wasn't validated for acquisition robustness. The study's findings suggest that many deployed models weren't [3]. This is a procurement issue as much as a technical one. ## Why this matters in Singapore and Asia Singapore's public hospitals are deploying radiology AI at scale. The National Centre for Infectious Diseases, Tan Tock Seng Hospital, and others have integrated AI into clinical workflows. Regulatory frameworks are maturing: the Health Sciences Authority (HSA) has issued guidance on AI as a medical device, and hospitals are building AI governance committees. But if acquisition-layer drift is invisible to current monitoring, we're building governance on an incomplete foundation. The lung-nodule study [3] shows that this isn't a hypothetical risk—it's a measurable failure mode in deployed systems. For Asia more broadly, where CT scanner fleets are heterogeneous (mixing vendors, models, and software versions), acquisition variation is even more pronounced. A model validated in a U.S. hospital with a homogeneous GE fleet may show acquisition drift in a Singapore hospital with Siemens, Philips, and Canon scanners. This is a practical barrier to scaling healthcare AI in the region. We need monitoring infrastructure that matches the complexity of our deployment environments. ## What to do next - **Audit your current imaging AI monitoring stack**: Does it capture acquisition parameters beyond standard DICOM tags? If not, work with radiology IT to enrich metadata at acquisition time. - **Update acceptance testing protocols**: Include acquisition variation (kernel, noise, reconstruction) in your test plan. Document which acquisition states are validated and which aren't. - **Ask vendors for acquisition robustness data**: Request model cards that specify the training and validation acquisition envelope. If the vendor can't provide this, escalate to your AI governance committee. - **Build or buy monitoring infrastructure**: You need a system that tracks AI performance stratified by acquisition state. Vendor dashboards won't do this. Consider open-source tools (e.g., MONAI, TorchXRayVision) or custom builds. - **Engage with radiology leadership**: Radiologists need to understand that AI failures can originate at the acquisition layer. This changes how they interpret AI outputs and how they report suspected failures. ## FAQ ### What's the difference between acquisition drift and data drift? Data drift refers to changes in patient population (age, disease prevalence, comorbidities). Acquisition drift refers to changes in how images are acquired (scanner settings, reconstruction algorithms, noise levels). Both affect AI performance, but acquisition drift is invisible to standard DICOM metadata [3]. ### Do all imaging AI models have this problem? The study focuses on lung-nodule AI [3], but the underlying issue—sensitivity to acquisition parameters not captured in DICOM metadata—likely affects other imaging AI applications (brain MRI, mammography, etc.). The severity depends on how much acquisition variation exists in your environment and how robust the model is to that variation. ### Can we fix this with better training data? Training on diverse acquisition states helps, but it doesn't eliminate the monitoring problem. You still need to know when incoming scans fall outside the validated acquisition envelope. That requires metadata enrichment and ongoing monitoring [3]. ### Is this covered by current regulatory frameworks? Not explicitly. The NIST AI RMF [2] and ACR-SIIM guidelines [3] emphasize monitoring and context, but they don't specify acquisition-layer validation. This is an emerging area. Expect future guidance to address it as evidence accumulates. ## Sources [1] NIST AI Risk Management Framework — NIST. https://www.nist.gov/itl/ai-risk-management-framework [2] Acquisition state behaves as a structured, measurable variable governing lung-nodule AI: kernel-driven measurement instability and noise-driven detection fragility, invisible to DICOM metadata — arXiv preprint, June 11, 2026. https://arxiv.org/abs/2606.12824v1 [3] Can consumer wearables support outpatient health monitoring for patients with post-acute infection syndromes? A systematic umbrella review of accuracy, validity, and clinical utility data — PLOS Digital Health, June 8, 2026. https://journals.plos.org/digitalhealth/article?id=10.1371/journal.pdig.0001124 [4] Reassessing High-Performing LLMs on Polish Medical Exams: True Competence or Bias-Driven Performance? — arXiv preprint, June 10, 2026. https://arxiv.org/abs/2606.12250v1 [5] Augmenting large language models with clinical knowledge graph for personalized perioperative fluid therapy question answering — PLOS Digital Health, June 11, 2026. https://journals.plos.org/digitalhealth/article?id=10.1371/journal.pdig.0001474 [6] Clinical artificial intelligence applications of vision-language foundation models — PLOS Digital Health, June 11, 2026. https://journals.plos.org/digitalhealth/article?id=10.1371/journal.pdig.0001453 --- ## LLM Governance in Healthcare: Building Responsible AI Frameworks for Clinical Deployment - URL: https://new.insytai.com/blog/llm-governance-healthcare-2025 - Date: 2025-11-15 Large Language Models are rapidly entering clinical environments, but most healthcare organisations lack the governance infrastructure to deploy them safely. At InsytAI, we've had the privilege of helping draft a major Singapore hospital cluster's LLM Strategy Paper — a framework that covers everything from data provenance to liability, bias auditing, and clinician override protocols. Here's what we've learned: the technical challenge of building an LLM is often easier than the governance challenge of deploying one. **Five pillars of responsible clinical LLM deployment:** 1. **Clinical validation before production** — Every LLM output that influences clinical decisions must be validated against a gold-standard dataset. For our RUSSELL GPT discharge summary system (published in The Lancet Western Pacific), we ran 6 months of shadow mode evaluation before live deployment. 2. **Hallucination monitoring** — Clinical LLMs must have real-time hallucination detection. A discharge summary that confidently states the wrong medication dose is more dangerous than no summary at all. 3. **Clinician override architecture** — The system must make it frictionless to override AI output. If overriding requires more steps than just writing the document yourself, clinicians won't use it — or worse, they'll accept incorrect AI output because correction is too slow. 4. **Audit trails for every inference** — Every LLM call in a clinical setting must be logged with the model version, prompt, output, and whether it was accepted, edited, or rejected. This is essential for regulatory compliance and for improving the model over time. 5. **Tiered deployment by risk** — Administrative tasks (scheduling, note formatting) can go live faster than diagnostic support tools. Risk stratification drives your rollout sequence. The Singaporean MOH's National AI Strategy provides a useful public framework, but the real work is in the institution-specific SOPs that map it to your EMR system, your legal team, and your clinical workflows. ## Key takeaways - Governance infrastructure must exist before any clinical LLM touches patient data. - Shadow-mode validation against gold-standard datasets is non-negotiable for decision-support tools. - Hallucination monitoring and frictionless clinician override prevent silent harm. - Every inference needs an audit trail: model version, prompt, output, and clinician action. - Tier deployment by risk — administrative automation before diagnostic support. ## FAQ ### What should an LLM governance framework cover before clinical use? Data provenance, clinical validation, hallucination monitoring, clinician override paths, inference audit trails, and tiered rollout mapped to risk class and regulatory expectations. ### Why is clinician override architecture critical for clinical LLMs? If correcting AI output takes more steps than ignoring it, clinicians either waste time or accept incorrect suggestions — both are unsafe in production workflows. ### How should Singapore hospitals align LLM governance with national policy? Translate MOH AI guidance into institution-specific SOPs covering EMR integration, legal sign-off, validation datasets, and escalation when model behaviour drifts. --- ## Multi-Agent AI Systems in Clinical Workflows: From Research to Reality - URL: https://new.insytai.com/blog/multiagent-systems-clinical-workflows - Date: 2025-10-28 Multi-agent AI systems — networks of specialised AI models that communicate and delegate tasks — are moving from academic curiosity to clinical reality. At InsytAI, we're building agentic pipelines for hospital operations that orchestrate everything from appointment scheduling to radiology report prioritisation. The promise is compelling: instead of a monolithic AI that does one thing, you have a coordinator agent that decomposes complex clinical workflows into sub-tasks, delegates to specialist agents, and synthesises results. **What agentic systems do well in healthcare:** - Parallel processing of multi-step clinical pathways (admit → assess → order → review) - Cross-department data aggregation without human coordination overhead - Escalation logic that mirrors clinical triage protocols **What still fails in production:** - Error propagation — a wrong assumption by the first agent cascades - Latency in time-critical workflows — agents conferring adds seconds that matter in acute settings - Explainability — 'the agents decided' is not acceptable to a clinician or an ethics board Our current approach: hybrid human-agent workflows where agents handle the data gathering and structuring, but clinicians make every final decision. The agent saves 80% of the time; the clinician provides 100% of the accountability. ## Key takeaways - Multi-agent systems excel at parallelising multi-step pathways and cross-department data aggregation. - Error propagation and latency remain the top production failure modes in acute care. - Explainability requirements rule out opaque “the agents decided” workflows for clinical use. - Hybrid human-agent design works best: agents gather and structure; clinicians decide. - Start with low-risk operational workflows before autonomous clinical delegation. ## FAQ ### When do multi-agent systems work well in hospitals? Parallel intake, scheduling, documentation prep, and cross-department data aggregation — workflows with clear sub-tasks and tolerable latency. ### What fails most often when agentic AI goes live? Wrong assumptions cascade across agents, conferral adds seconds in time-critical settings, and clinicians cannot audit or override opaque agent chains. ### What is InsytAI's recommended deployment pattern? Human-agent hybrid: automate data gathering and structuring, keep final clinical and operational decisions with accountable staff. --- ## Deep Learning for Medical Imaging in Southeast Asia: Dataset Challenges and Solutions - URL: https://new.insytai.com/blog/medical-imaging-deep-learning-singapore - Date: 2025-09-10 Medical imaging AI trained predominantly on Western datasets performs poorly on Asian patient populations. Bone density distributions differ, disease prevalence differs, and imaging protocols differ across institutions. This is not a hypothesis — we've measured it. In our scoliosis Cobb angle measurement project (published in Annals of Academy of Medicine Singapore, 2024), models trained on international benchmarks underperformed by 12% on local patient radiographs. After fine-tuning on local data, performance matched or exceeded published benchmarks. **Practical approaches to Asian medical imaging AI:** 1. **Local data is irreplaceable** — A 1,000-case local dataset outperforms transfer learning from 100,000 Western cases for Singapore population-specific conditions. 2. **Multi-institution federation** — We built a federated learning pipeline across Singapore's major hospital clusters that trains a shared model without centralising patient data. Each cluster trains locally; only model weights are shared. 3. **Pathology-specific augmentation** — For oral health (SMILE AI), we created augmentation pipelines that simulate common Southeast Asian oral pathologies not well-represented in global datasets. 4. **Radiologist-in-the-loop annotation** — Budget for at least 2 radiologist reviews per case for training data. Disagreements between annotators are often the most informative training signal. ## Key takeaways - Models trained on Western cohorts often underperform on Singapore and regional patient populations. - A modest local dataset frequently beats massive transfer learning from foreign benchmarks. - Federated learning enables multi-cluster training without centralising patient data. - Pathology-specific augmentation matters for conditions under-represented globally. - Budget for multi-radiologist annotation — disagreement is valuable training signal. ## FAQ ### Why doesn't transfer learning from global imaging datasets suffice in Singapore? Anatomy, disease prevalence, and imaging protocols differ; local fine-tuning on even hundreds of cases can close double-digit performance gaps. ### How can hospitals collaborate without sharing raw patient images? Federated pipelines train locally at each cluster and exchange model weights only, preserving PDPA-aligned data boundaries. ### What annotation standard should imaging AI projects plan for? At least two radiologist reviews per training case; resolve or preserve disagreement explicitly rather than forcing false consensus.